Aton Pharma signs up distributor for Asia Pacific region
Aton Pharma,a US specialty drugmaker, has signed a marketing and distribution agreement with PharmaLink Asia Pacific to enable it to expand distribution into several countries in Asia and Australia.
"This partnership marks an important milestone for Aton as we execute our mission to expand access to our medically essential portfolio of products," said Michael Wells, chief executive of Aton, noting that PharmaLink is uniquely qualified to help us expand our reach into the Asia Pacific region."
Aton provides essential therapies for under-treated diseases and rare illnesses around the world. Its portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze